Literature DB >> 22718512

Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systematic review and meta-analysis.

Ke-Qing Shi1, Yu-Chen Fan, Wen-Yue Liu, Ling-Fei Li, Yong-Ping Chen, Ming-Hua Zheng.   

Abstract

Evidences from randomized controlled trials (RCTs) for the efficiency of traditional Chinese medicine (TCM) on the treatment of nonalcoholic fatty liver disease (NAFLD) are conflicting. Here we conducted a systematic review and meta-analysis of RCTs to evaluate the efficiency and safety of TCM in the treatment of NAFLD. Studies were searched on PubMed and China National Knowledge Infrastructure from January 1995 to June 2010. RCTs comparing either TCM formulations alone or in combination with placebo, ursodeoxycholic acid, insulin sensitizers, lipid-lowering drugs, or antioxidants were included. The category of most usually used herbs in the treatment of NAFLD was also calculated. Five thousand nine hundred and four patients from 62 RCTs were included for meta-analysis and 25,661 patients from 419 clinical studies were for TCM formulation analysis. Comparing with western medicines mentioned above, TCM had a better effect on the normalization of alanine aminotransferase and disappearance of radiological steatosis in the treatment of NAFLD. Furthermore, 246 kinds of Chinese herbs were included in our present study, with an average of 10 herbs (range 1-31) in each formulation. Hawthorn Fruit (321 times in 17,670 patients) was the most often used herb in the treatment of NAFLD. In conclusion, TCM is of modest benefit to the treatment of NAFLD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22718512     DOI: 10.1007/s11033-012-1836-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  27 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 2.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

3.  Randomization, permuted blocks, masking, allocation concealment, and selection bias in the Tobacco Quit Line Study.

Authors:  Vance W Berger
Journal:  Contemp Clin Trials       Date:  2010-02-25       Impact factor: 2.226

Review 4.  Biological analysis of herbal medicines used for the treatment of liver diseases.

Authors:  Chao-Feng Chien; Yu-Tse Wu; Tung-Hu Tsai
Journal:  Biomed Chromatogr       Date:  2011-01       Impact factor: 1.902

5.  Stress signaling in the methionine-choline-deficient model of murine fatty liver disease.

Authors:  Russell K Soon; Jim S Yan; James P Grenert; Jacquelyn J Maher
Journal:  Gastroenterology       Date:  2010-08-01       Impact factor: 22.682

6.  Rhaponticin from rhubarb rhizomes alleviates liver steatosis and improves blood glucose and lipid profiles in KK/Ay diabetic mice.

Authors:  Jinlong Chen; Mengmeng Ma; Yanwei Lu; Lisheng Wang; Chutse Wu; Haifeng Duan
Journal:  Planta Med       Date:  2009-02-23       Impact factor: 3.352

7.  Effects of traditional Chinese medicines on serum lipid profiles and homocysteine in the ovariectomized rats.

Authors:  Su-Chen Lee; Shun-Jen Chang; Li-Yu Tsai
Journal:  Am J Chin Med       Date:  2004       Impact factor: 4.667

8.  Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT.

Authors:  Ioannis Kyrlagkitsis; Bernard Portmann; Heather Smith; John O'Grady; Matthew E Cramp
Journal:  Am J Gastroenterol       Date:  2003-07       Impact factor: 10.864

Review 9.  Engaging parents to increase youth physical activity a systematic review.

Authors:  Teresia M O'Connor; Russell Jago; Tom Baranowski
Journal:  Am J Prev Med       Date:  2009-08       Impact factor: 5.043

10.  The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects.

Authors:  Ki Chul Sung; Marno C Ryan; Andrew M Wilson
Journal:  Atherosclerosis       Date:  2008-07-31       Impact factor: 5.162

View more
  32 in total

Review 1.  Integrative Medicine for Gastrointestinal Disease.

Authors:  Michelle L Dossett; Ezra M Cohen; Jonah Cohen
Journal:  Prim Care       Date:  2017-06       Impact factor: 2.907

Review 2.  Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

Authors:  Carly E Kelley; Ann J Brown; Anna Mae Diehl; Tracy L Setji
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

3.  Chinese medicine formulas for nonalcoholic fatty liver disease: Overview of systematic reviews.

Authors:  Liang Dai; Wen-Jun Zhou; Linda L D Zhong; Xu-Dong Tang; Guang Ji
Journal:  World J Clin Cases       Date:  2021-01-06       Impact factor: 1.337

4.  Insights into the molecular mechanisms of Polygonum multiflorum Thunb-induced liver injury: a computational systems toxicology approach.

Authors:  Yin-Yin Wang; Jie Li; Zeng-Rui Wu; Bo Zhang; Hong-Bin Yang; Qin Wang; Ying-Chun Cai; Gui-Xia Liu; Wei-Hua Li; Yun Tang
Journal:  Acta Pharmacol Sin       Date:  2017-02-27       Impact factor: 6.150

5.  Aptamer-Based High-Throughput Screening Model for Efficient Selection and Evaluation of Natural Ingredients against SGIV Infection.

Authors:  Hongling Wei; Zhongbao Guo; Yu Long; Mingzhu Liu; Jun Xiao; Lin Huang; Qing Yu; Pengfei Li
Journal:  Viruses       Date:  2022-06-08       Impact factor: 5.818

6.  Methyltransferase SETD2 mediates hepatoprotection of berberine against steatosis.

Authors:  Li Dai; Shuang Lu; Tianbai Shen; Ying Li; Jianjie Chen
Journal:  Ann Transl Med       Date:  2022-05

7.  Hugan Qingzhi Exerts Anti-Inflammatory Effects in a Rat Model of Nonalcoholic Fatty Liver Disease.

Authors:  WaiJiao Tang; Lu Zeng; JinJin Yin; YuFa Yao; LiJuan Feng; XiaoRui Yao; XiaoMin Sun; BenJie Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-14       Impact factor: 2.629

8.  Treatment of rats with Jiangzhi Capsule improves liquid fructose-induced fatty liver: modulation of hepatic expression of SREBP-1c and DGAT-2.

Authors:  Yuanyang Zhao; Yongquan Pan; Yifan Yang; Robert Batey; Jianwei Wang; Yuhao Li
Journal:  J Transl Med       Date:  2015-06-02       Impact factor: 5.531

9.  Global publication trends and research hotspots of nonalcoholic fatty liver disease: a bibliometric analysis and systematic review.

Authors:  Tong-Shuo Zhang; Hua-Lei Qin; Tong Wang; Hai-Tao Li; Hai Li; Shi-Hai Xia; Xiao-Hui Xiang
Journal:  Springerplus       Date:  2015-12-14

10.  Effects of Soothing Liver and Invigorating Spleen Recipes on the IKKβ-NF-κB Signaling Pathway in Kupffer Cells of Nonalcoholic Steatohepatitis Rats.

Authors:  Xiang-Wen Gong; Yong-Jian Xu; Qin-He Yang; Yin-Ji Liang; Yu-Pei Zhang; Guan-Long Wang; Yuan-Yuan Li
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-04       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.